Loading transcript...
Click for full transcript
Chapters & Sections (51)
▼
0:00
Medicare Prescription Drug Spending Basics
0:39
Bipartisan Budget Act and Inflation Reduction Act
1:08
Medicare Prescription Drug Pricing Debate
1:42
US Healthcare Spending and Medicare Growth
2:23
US Debt to GDP Ratio Concerns
3:05
Federal Deficits Driven by Healthcare Spending
3:52
Federal Spending vs Revenues as Share of GDP
4:44
Federal Deficits and Prescription Drug Spending
5:24
Medicare Prescription Drug Spending Growth
5:59
Medicare Prescription Drug Spending Growth Concerns
6:52
Medicare Part B Drug Pricing Comparison
7:35
Medicare Drug Pricing and Patent Exclusivity
8:15
Patent System and Drug Pricing
9:03
Balancing Innovation and Affordable Medication Prices
9:46
High Drug Prices Limit Innovation Benefits
10:35
Concerns about High Prices and Innovation
11:04
Medicare Drug Price Reduction Efforts
12:06
Coverage Gap in Part D Explained
12:42
Medicare Negotiates Lower Prescription Drug Prices
13:51
Medicare's Ability to Negotiate Drug Prices
14:30
Medicare Negotiates Drug Prices with Pharmaceutical Companies
14:56
Negotiations between Congress and Drug Companies
15:41
Critique of Central Economic Planning
16:36
Medicare Program Inflates Drug Prices Significantly
17:18
Potential Impact of Direct Healthcare Payments
17:46
Medicare and Prescription Drug Prices
18:21
Companies Complaining About Price Reductions
18:46
Potential Negative Impact of Price Negotiation
19:37
Medicare Price Negotiation Delayed for 60 Years
20:14
Medicare Prescription Drug Spending Growth Projections
20:51
Medicare Spending and Prescription Drug Prices
21:59
Industry Lobbying to Defang Medicare Cuts
22:45
Healthcare Industry Influence on Capitol Hill
23:17
Lobbying Expenditures by Economic Sector
23:46
Lobby Influence on Capitol Hill
24:31
Fizer Ad During Super Bowl
25:02
Charles Fizer Co-Founders Relationship